EXECUTIVE ENGAGEMENTS
POOL
11366
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
1364
Interactions with Platform & by Email
PARTICIPANTS
341
Unique # Participated
VALIDATIONS
86
Responses Validated*
COMPANIES
76
Responses Validated*
* Login for a full stack data experience
DATE
JAN 2022
TABLES
202
PAGES
292
EDITION
15
PRICE
USD 5600
CODE
MCP-6503
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
HIGHLIGHTS & REPORT INDEX
What's New for 2022?
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Amid the COVID-19 crisis, the global market for Pediatric Drugs and Vaccines estimated at US$106.2 Billion in the year 2020, is projected to reach a revised size of US$176.3 Billion by 2027, growing at a CAGR of 7.5% over the analysis period 2020-2027. Conjugate, one of the segments analyzed in the report, is projected to record a 8.7% CAGR and reach US$58.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Live Attenuated segment is readjusted to a revised 7.7% CAGR for the next 7-year period.
The Pediatric Drugs and Vaccines market in the U.S. is estimated at US$28.7 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$39.8 Billion by the year 2027 trailing a CAGR of 11.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4% and 6.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.
In the global Inactivated segment, USA, Canada, Japan, China and Europe will drive the 6.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$11.9 Billion in the year 2020 will reach a projected size of US$18.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$24.2 Billion by the year 2027, while Latin America will expand at a 8.6% CAGR through the analysis period.
SELECT PLAYERS
Abbott Laboratories; Allergan Inc.; Amgen Inc.; AstraZeneca Plc; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genentech Inc.; GlaxoSmithKline Plc; Janssen Biologics B.V; Merck & Co. Inc.; Novartis AG; Novo Nordisk A/S; Pfizer Inc.; Sanofi; Shionogi Inc.; Shire Pharmaceuticals Group Plc
SEGMENTS
» Technology (Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid, Other Technologies) » Product Type (Vaccines, Drugs)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Pediatrics: A Highly Underserved and Undervalued Group |
| Recent Market Activity |
| Pediatric Drugs Market - An Abode of Opportunities |
| The United States: Largest Market for Pediatric Drugs and Vaccines |
| Developing Markets to Witness Faster Growth |
| Antibiotics: Largest Selling Drug Classes |
| Pediatric Vaccines Market - On High Growth Trajectory |
| Supply and Demand Dynamics of the Global Vaccine Market |
| UNICEF Addresses BCG Vaccine Supply Shortage |
| Access to Vaccines Index: Aiding Increased Access to Vaccines |
| Recent Advancements/Achievements in the Pediatric Vaccines Space |
| Pediatric Drugs and Vaccines – Global Key Competitors Percentage Market Share in 2022 (E) |
| Impact of Covid-19 and a Looming Global Recession |
| Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
| 2. FOCUS ON SELECT PLAYERS |
| Abbott Laboratories (USA) |
| Allergan, Inc. (USA) |
| Amgen, Inc. (USA) |
| AstraZeneca Plc. (UK) |
| Boehringer Ingelheim GmbH (Germany) |
| Bristol-Myers Squibb Company (USA) |
| Eli Lilly and Company (USA) |
| F. Hoffmann-La Roche Ltd (Switzerland) |
| Genentech, Inc. (USA) |
| GlaxoSmithKline plc. (UK) |
| Janssen Biologics B.V. (USA) |
| Actelion Pharmaceuticals Ltd (Switzerland) (A Janssen Pharmaceutical Company) |
| Merck & Co., Inc. (USA) |
| Novartis AG (Switzerland) |
| Novo Nordisk A/S (Denmark) |
| Pfizer, Inc. (USA) |
| Sanofi S.A (France) |
| Shionogi Inc. (USA) |
| Shire Pharmaceuticals Group Plc. (UK) |
| 3. MARKET TRENDS & DRIVERS |
| Pediatric Exclusivity Drives Manufacturers’ Interest |
| Pediatric Exclusitivity Granted to Branded Drugs |
| New Product Approvals and Pipeline - A Key Growth Propeller |
| Recent Pediatric Drug Approvals: 2015-2017 |
| Pediatric Drug Approvals: 2011-2014 |
| Phase III Completed Pediatric Drugs: 2015-2017 (As of July 2017) |
| Ongoing Phase III Pediatric Drugs Clinical Trials: 2015-2017 (As of July 2017) |
| Potential for Pediatric Drugs Against Obesity-related Conditions |
| List of Pediatric Drugs for Congestive Heart Failure Treatment |
| Recent Findings to Help Save Children’s Lives |
| Challenges of Pediatric Drug Development: Formulation Problems and Ethical Constraints of Clinical Trials |
| Financial Enticement for Drug Makers to Conduct Dedicated Pediatric Trials |
| Modeling & Simulation - A Powerful Tool for Pediatric Clinical Study Sponsors |
| Pharmacometrics Approaches Gain Traction Among US and EU Researchers |
| Challenges Associated with Adoption of Pharmacometric Approach |
| Guidelines for Conducting Ethically Correct Clinical Trials |
| Pediatric Drug Market - Is Off-label Prescription Justified? |
| Indian Drug Manufacturers Develop Pneumococcal Conjugate Vaccine |
| High Vaccination Costs: A Major Hindrance for Pneumonia Vaccination |
| Vaccine Refusal by Parents - A Growing Trend in the US Market |
| Orphan Drugs for Pediatric Use Gain Popularity |
| List of FDA Approved Orphan Drugs: 2015-2016 |
| List of FDA Designated Orphan Drugs: 2015-2017 |
| Pediatric Review Vouchers Foster Innovation in Rare Pediatric Drugs |
| Need for Higher Focus on Fixed-Dose Combination for Pediatric HIV Infections |
| Approved Pediatric Antiretroviral Drugs for HIV Treatment |
| Highly Fragmented Growth Hormone Market |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Pediatric Drugs and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Conjugate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Live Attenuated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Inactivated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Subunit by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Toxoid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Toxoid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Toxoid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
| USA Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| USA Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Canada Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| JAPAN |
| Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
| Japan Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Japan Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| CHINA |
| Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
| China Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| China Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| EUROPE |
| Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
| Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Pediatric Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| FRANCE |
| Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
| France Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| France Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| GERMANY |
| Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
| Germany Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Germany Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Italy Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| UNITED KINGDOM |
| Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
| UK Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| UK Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| SPAIN |
| Spain Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Spain Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Spain 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Spain Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Spain Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Spain 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| RUSSIA |
| Russia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Russia Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Russia 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Russia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Russia Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Russia 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Rest of Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| ASIA-PACIFIC |
| Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027 |
| Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| AUSTRALIA |
| Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E) |
| Australia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Australia Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Australia 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Australia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Australia Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Australia 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| INDIA |
| Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E) |
| India Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| India Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| India 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| India Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| India Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| India 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| SOUTH KOREA |
| South Korea Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| South Korea Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| South Korea 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| South Korea Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| South Korea Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| South Korea 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| REST OF ASIA-PACIFIC |
| Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Asia-Pacific 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Asia-Pacific 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| LATIN AMERICA |
| Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E) |
| Latin America Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for Pediatric Drugs and Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027 |
| Latin America Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Latin America Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| ARGENTINA |
| Argentina Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Argentina Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Argentina 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Argentina Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Argentina Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Argentina 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| BRAZIL |
| Brazil Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Brazil Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Brazil 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Brazil Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Brazil Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Brazil 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| MEXICO |
| Mexico Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Mexico Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Mexico 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Mexico Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Mexico Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Mexico 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| REST OF LATIN AMERICA |
| Rest of Latin America Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Latin America Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Latin America 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Rest of Latin America Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Latin America Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Latin America 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| MIDDLE EAST |
| Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E) |
| Middle East Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for Pediatric Drugs and Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2021 & 2027 |
| Middle East Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Middle East Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| IRAN |
| Iran Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Iran Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Iran 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Iran Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Iran Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Iran 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| ISRAEL |
| Israel Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Israel Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Israel 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Israel Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Israel Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Israel 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| SAUDI ARABIA |
| Saudi Arabia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Saudi Arabia Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Saudi Arabia 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Saudi Arabia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Saudi Arabia Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Saudi Arabia 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| UNITED ARAB EMIRATES |
| UAE Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UAE Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UAE 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| UAE Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UAE Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UAE 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| REST OF MIDDLE EAST |
| Rest of Middle East Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Middle East Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Middle East 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Rest of Middle East Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Middle East Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Middle East 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| AFRICA |
| Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E) |
| Africa Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Africa Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Africa 15-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2012, 2021 & 2027 |
| Africa Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Africa Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Africa 15-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2012, 2021 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 76 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com